Programming Dendritic Cells to Expose the Persistent HIV-1 Latent Reservoir for Immune Targeting
对树突状细胞进行编程以暴露持久的 HIV-1 潜伏库以实现免疫靶向
基本信息
- 批准号:9347740
- 负责人:
- 金额:$ 23.34万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-08-01 至 2019-07-31
- 项目状态:已结题
- 来源:
- 关键词:Acute DiseaseAddressAdjuvantAffectAntigen PresentationAntigensAutologousAutologous Dendritic CellsBiological AssayCD4 Positive T LymphocytesCell TherapyCellsChronicClinicalClinical ResearchClinical TrialsCoculture TechniquesCytomegalovirusCytotoxic T-LymphocytesDendritic CellsDendritic cell activationDevelopmentDiseaseEffectivenessEffector CellGenetic TranscriptionHIVHIV AntigensHIV InfectionsHIV SeropositivityHIV vaccineHIV-1Half-LifeHighly Active Antiretroviral TherapyImmuneImmune TargetingImmunityImmunologic SurveillanceImmunotherapyIn VitroIndividualInfectionInflammatoryInterruptionLifeLinkLymphocyteMalignant NeoplasmsMediatingMethodsModelingParticipantPharmacologyPlayPredispositionRegulationReportingResidual stateResourcesRestRoleSpecificityStaphylococcal Enterotoxin BSystemT-LymphocyteTestingThe Multicenter AIDS Cohort StudyTherapeuticTimeLineViralViral reservoirViremiaVirusVirus Diseasesbasecell typeclinical applicationclinically relevantdesignin vitro Modelin vivokillingsmennovelnovel strategiespathogenpolarized cellpre-clinicalpressureprotein expressionpurgeresponsesensorsuccesstherapeutic targettherapy designvaccine trial
项目摘要
PROJECT SUMMARY/ABSTRACT
While current therapies to treat chronic HIV infection are effective at controlling the virus, the disease is still not
curable, and there is a life-long Despite the success of highly active anti-retroviral therapy (HAART), over 36
million people currently live with HIV infection, which is now managed as a chronic rather than acute disease,
but requires a lifelong commitment to HAART. The latent reservoir of replication-competent HIV in HAART-
suppressed individuals is considered a critical barrier to a cure, due to the long half-life and persistence of the
infected CD4+ T cell reservoir. Moreover, in its latent state, the lack of viral transcription and protein expression
in the infected targets allows the reservoir to escape immune surveillance. The ‘kick and kill’ approach to curing
or controlling HIV involves inducing HIV latency reversal during HAART to expose the infected cells, while
creating an arsenal of immune effector cells, such as cytotoxic T cell lymphocytes (CTL), capable of eliminating
these targets. Finding an effective pharmacologic means to expose and purge the viral reservoir in a non-toxic
manner has been elusive and remains major barrier to this cure approach. While dendritic cells (DC) have been
used safely in clinical trials to drive CTL responses in the settings of cancer and HIV, a recent report by our
group linked the administration of a DC-based HIV vaccine with increased residual viremia in HAART-
suppressed individuals following analytic treatment interruption, suggesting that the DC-based therapeutic acted
as an LRA. However, that clinical study was not designed to specifically address the use of the DC therapeutic
as an LRA, and a number of important questions remain including the roles that DC polarization and antigen
presentation played in this effect, the particular CD4 T cell reservoir that was affected, and the underlying
mechanisms involved. In this proposal, we will investigate the use of two clinically applicable differentially
polarized DC types as an in vitro approach to induce HIV re-activation in latently infected CD4+ T cells utilizing
cells obtained from virally suppressed HIV-1 positive MACS participants. We will determine the optimal DC
activation strategy to promote their LR function, assess CD4+ T cell subsets affected by the DC-based LRA
approach, explore the role of antigen presentation the system, and perform novel assays to qualitatively assess
DC exposure of the HIV-1 reservoir for CTL targeting. Information from these studies will ultimately be used in
development of a personalized DC-based cellular therapy designed to facilitate both the ‘kick’ and ‘kill’ of the HIV-
1 reservoir as a strategy towards curing or controlling chronic HIV-1 infection.
项目总结/摘要
虽然目前治疗慢性艾滋病毒感染的疗法在控制病毒方面是有效的,但这种疾病仍然不是
尽管高效抗逆转录病毒疗法(HAART)取得了成功,但超过36
目前有1000万人感染艾滋病毒,艾滋病毒现在作为慢性病而不是急性病来管理,
但需要终生致力于HAART。HAART中具有复制能力的HIV的潜在储存库-
受抑制的个体被认为是治愈的关键障碍,这是由于受抑制的个体的长半衰期和持久性。
感染的CD 4 + T细胞库。此外,在其潜伏状态下,缺乏病毒转录和蛋白质表达,
使宿主逃脱免疫监视。“踢和杀”的治疗方法
或控制HIV涉及在HAART期间诱导HIV潜伏期逆转以暴露受感染的细胞,
产生免疫效应细胞,如细胞毒性T细胞淋巴细胞(CTL),能够消除
这些目标。找到一种有效的药理学方法,以无毒的方式暴露和清除病毒库,
方式一直难以捉摸,并且仍然是这种治愈方法的主要障碍。树突状细胞(DC)
在临床试验中安全地用于在癌症和HIV背景下驱动CTL应答,我们的研究人员最近的一份报告显示,
研究小组将基于DC的HIV疫苗的施用与HAART中残留病毒血症的增加联系起来,
在分析治疗中断后,受抑制的个体,这表明基于DC的治疗剂
作为一个爱尔兰共和军。然而,该临床研究并不是专门针对DC治疗剂的使用而设计的。
作为LRA,还有一些重要的问题,包括DC极化和抗原
在这种效应中,特定的CD 4 T细胞库受到影响,以及潜在的
涉及的机制。在本提案中,我们将研究两种临床适用的差异
极化DC类型作为体外方法诱导潜伏感染的CD 4 + T细胞中的HIV再活化,
从病毒抑制的HIV-1阳性MACS参与者获得的细胞。我们将确定最佳DC
激活策略,以促进其LR功能,评估基于DC的LRA对CD 4 + T细胞亚群的影响
方法,探索抗原呈递系统的作用,并进行新的测定,以定性评估
用于CTL靶向的HIV-1储库的DC暴露。这些研究的信息最终将用于
开发基于DC的个性化细胞疗法,旨在促进HIV的“踢”和“杀”,
1水库作为治疗或控制慢性HIV-1感染的策略。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Robbie B Mailliard其他文献
Naive CD8+ T cells from ART respond to primary vaccination against autologous HIV-1 antigen
- DOI:
10.1186/1742-4690-9-s1-p16 - 发表时间:
2012-05-25 - 期刊:
- 影响因子:3.900
- 作者:
Kellie N Smith;Robbie B Mailliard;Weimin Jiang - 通讯作者:
Weimin Jiang
Robbie B Mailliard的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Robbie B Mailliard', 18)}}的其他基金
Immune response to COVID-19 vaccine in HIV infected men and women
HIV 感染男性和女性对 COVID-19 疫苗的免疫反应
- 批准号:
10686994 - 财政年份:2021
- 资助金额:
$ 23.34万 - 项目类别:
Immune response to COVID-19 vaccine in HIV infected men and women
HIV 感染男性和女性对 COVID-19 疫苗的免疫反应
- 批准号:
10494217 - 财政年份:2021
- 资助金额:
$ 23.34万 - 项目类别:
Immune response to COVID-19 vaccine in HIV infected men and women
HIV 感染男性和女性对 COVID-19 疫苗的免疫反应
- 批准号:
10402431 - 财政年份:2021
- 资助金额:
$ 23.34万 - 项目类别:
Analysis of Cell Sense Labeled Human Cells
Cell Sense 标记的人体细胞的分析
- 批准号:
7481330 - 财政年份:2008
- 资助金额:
$ 23.34万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 23.34万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 23.34万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 23.34万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 23.34万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 23.34万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 23.34万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 23.34万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 23.34万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 23.34万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 23.34万 - 项目类别:
Research Grant